How to buy Orchard Therapeutics stock

Orchard Therapeutics plc is a biotechnology business based in the US. Orchard Therapeutics shares (ORTX) are listed on the NASDAQ and all prices are listed in US Dollars. Orchard Therapeutics employs 224 staff and has a trailing 12-month revenue of around USD$2.6 million.

How to buy shares in Orchard Therapeutics

1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
3. Search for Orchard Therapeutics. Find the stock by name or ticker symbol: ORTX. Research its history to confirm it's a solid investment against your financial goals.
4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Orchard Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Orchard Therapeutics, depending on your broker.
6. Check in on your investment. Congratulations, you own a part of Orchard Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Orchard Therapeutics share price

Use our graph to track the performance of ORTX stocks over time.

Orchard Therapeutics shares at a glance

• Key figures

Information last updated 2021-04-16.

52-week range	USD$3.76 - USD$12.377
50-day moving average	USD$7.3976
200-day moving average	USD$5.7964
Wall St. target price	USD$15.11
PE ratio	N/A
Dividend yield	N/A (0%)
Earnings per share (TTM)	USD$-2.273

Buy Orchard Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Orchard Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Orchard Therapeutics plc by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Orchard Therapeutics financials

Revenue TTM	USD$2.6 million
Gross profit TTM	USD$1.7 million
Return on assets TTM	-26.5%
Return on equity TTM	-63.64%
Profit margin	0%
Book value	$1.816
Market capitalisation	USD$784.2 million

TTM: trailing 12 months

Shorting Orchard Therapeutics shares

There are currently 4.8 million Orchard Therapeutics shares held short by investors – that's known as Orchard Therapeutics's "short interest". This figure is 10.2% down from 5.3 million last month.

There are a few different ways that this level of interest in shorting Orchard Therapeutics shares can be evaluated.

Orchard Therapeutics's "short interest ratio" (SIR)

Orchard Therapeutics's "short interest ratio" (SIR) is the quantity of Orchard Therapeutics shares currently shorted divided by the average quantity of Orchard Therapeutics shares traded daily (recently around 1.1 million). Orchard Therapeutics's SIR currently stands at 4.52. In other words for every 100,000 Orchard Therapeutics shares traded daily on the market, roughly 4520 shares are currently held short.

However Orchard Therapeutics's short interest can also be evaluated against the total number of Orchard Therapeutics shares, or, against the total number of tradable Orchard Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Orchard Therapeutics's short interest could be expressed as 0.04% of the outstanding shares (for every 100,000 Orchard Therapeutics shares in existence, roughly 40 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Orchard Therapeutics shares, roughly 0 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Orchard Therapeutics.

Find out more about how you can short Orchard Therapeutics stock.

Orchard Therapeutics share dividends

We're not expecting Orchard Therapeutics to pay a dividend over the next 12 months.

Orchard Therapeutics share price volatility

Over the last 12 months, Orchard Therapeutics's shares have ranged in value from as little as $3.76 up to $12.377. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Orchard Therapeutics's is 1.2305. This would suggest that Orchard Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

Orchard Therapeutics overview

Orchard Therapeutics plc, a biopharmaceutical company, develops gene therapies for serious and life-threatening rare diseases in the United Kingdom, European Union, and the United States. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified cellular drug product to treat the patient's disease through a single administration. It provides Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-203 for mucopolysaccharidosis type I, OTL-201 for mucopolysaccharidosis type MPS-IIIA, and OTL-202 for mucopolysaccharidosis type IIIB. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.

Frequently asked questions

• What percentage of Orchard Therapeutics is owned by insiders or institutions?

  Currently 0.246% of Orchard Therapeutics shares are held by insiders and 62.644% by institutions.

• How many people work for Orchard Therapeutics?

  Latest data suggests 224 work at Orchard Therapeutics.

• When does the fiscal year end for Orchard Therapeutics?

  Orchard Therapeutics's fiscal year ends in December.

• Where is Orchard Therapeutics based?

  Orchard Therapeutics's address is: 108 Cannon Street, London, United Kingdom, EC4N 6EU

• What is Orchard Therapeutics's ISIN number?

  Orchard Therapeutics's international securities identification number is: US68570P1012

• What is Orchard Therapeutics's CUSIP number?

  Orchard Therapeutics's Committee on Uniform Securities Identification Procedures number is: 68570P101